Full Press Release Details
BriaCell Partners with Caris Life Sciences
Outreach and Molecular Profiling
PHILADELPHIA, PA and VANCOUVER, British Columbia,
September 14, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"),
a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has signed an agreement
with Caris Life Sciences (Caris), a leading molecular science and technology company actively developing and delivering innovative
solutions to revolutionize healthcare.
"Our goal is to develop immunotherapies that
are personalized for each patient, and Caris' extensive library of clinical data, cutting-edge biomarker technology, and expertise
will be invaluable in achieving our objectives," stated Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer. "We
expect Caris' unique platform to help us identify patients who do not respond to existing treatments and are more likely to benefit
from our immunotherapy treatments."
Under the terms of the agreement, Caris will help
BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic
breast cancer of certain genetically defined subgroups. The partnership between BriaCell and Caris leverages Caris' Right-In-Time
(RIT) Clinical Trial Network, a group of over 495 oncology sites that are able to quickly identify
and enroll eligible patients in biomarker-directed clinical trials. This service offers patients and physicians access to the most
cutting-edge precision medicine in development. Additionally, through Caris' comprehensive molecular profiling (Whole Exome and
Whole Transcriptome Sequencing), Caris will perform tumor profiling for the patients enrolled in the clinical trial.
is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
About Caris Life Sciences
Caris Life Sciences (Caris)
is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare
and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application
of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and
cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource
and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy
selection and drug development to improve the human condition.
With a primary focus on cancer,
Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that
helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based,
circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome
Sequencing from blood) and serial monitoring - making it the most powerful liquid biopsy assay ever developed.
in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services
throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or
follow Caris on Twitter (@CarisLS).
release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other
than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading
"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading
"Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties"
in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission,
all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking
statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither Toronto Stock Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy
William V. Williams, MD
Director of Public Relations
Investor Relations Contact:
Caris Life Sciences Media Contact: